Abbott Laboratories vs. Ultragenyx Pharmaceutical Inc.
Abbott Laboratories (ABT) comes out ahead, leading on 5 of 8 compared factors.
Size & Scale
| ABT | RARE | |
|---|---|---|
| Market Cap | $191.92 billion | $2.65 billion |
| Revenue (TTM) | $46.59 billion | $717.21 million |
| Net Income (TTM) | $5.42 billion | $-585,969,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | RARE | |
|---|---|---|
| P/E Ratio | 36.00 | — |
| Price / Book | 3.71 | -9.10 |
| Price / Sales | 4.12 | 3.69 |
RARE leads on 2 of 2 valuation factors.
Profitability
| ABT | RARE | |
|---|---|---|
| Net Margin | 11.65% | -81.70% |
| Return on Equity | 10.48% | 201.36% |
ABT and RARE split the profitability factors evenly.
Dividend
| ABT | RARE | |
|---|---|---|
| Dividend Yield | 2.27% | — |
| Payout Ratio | 81.55 | — |
ABT and RARE split the dividend factors evenly.
Risk & Sentiment
| ABT | RARE | |
|---|---|---|
| Short Interest | 0.57% | 5.60% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, RARE overview, RARE financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.